Hallo,
habe gerade zwei Studien zu FLT3-ITD gefunden, die in Frankreich und Hongkong mit Ponatinib aufgelegt werden. Sind lt. der Homepage von Ariad noch nicht offen.
http://www.ariad.com/investigator_sponsored_trials
Phase 2 Study of Ponatinib with Cytarabine as Consolidation Therapy in Patients with FLT3-ITD AML
Not yet open for enrollment
Study Design: Non-randomized, open-label, multi-center, dose-escalation phase 1–2 trial
Patients: Patients with FLT3-ITD AML in first complete remission
Purpose: To assess the safety and efficacy of ponatinib in combination with high- or intermediate-dose cytarabine as consolidation therapy for patients with intermediate-risk cytogenetic FLT3-ITD AML
Locations: Hôpitaux de Versailles, Hôpital Mignot, France; approximately 45 ALFA and GOELAM clinical centers
Phase 2 Study of Ponatinib in FLT3-ITD AML Relapsed or Refractory After Standard Chemotherapy
Not yet open for enrollment
Study Design: Non-randomized, open-label, single-center
Patients: Patients with FLT3-ITD+ AML relapsed after or refractory to at least two standard chemotherapy regimens or unfit for chemotherapy
Purpose: To assess the safety and efficacy of ponatinib in relapsed or refractory FLT3-ITD+ AML with a view to achieving remission and bridging patients to allogeneic hematopoietic stem cell transplantation
Location: Queen Mary Hospital, Hong Kong
Ob da die eigene Erkrankung zu passt, kann nur ein Onkologe beantworten oder entscheiden.
Schätze aber, dass nicht alle Onkologen alle Studien kennen.
Also meinerseits nur zur Info und ggf. weiterer, eigener Recherche.